These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 15642569)
1. Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator. Pratt CM; Dorian P; Al-Khalidi HR; Brum JM; Borggrefe M; Tatla DS; Brachmann J; Myerburg RJ; Cannom DS; Holroyde MJ; van der Laan M; Hohnloser SH; Am J Cardiol; 2005 Jan; 95(2):274-6. PubMed ID: 15642569 [TBL] [Abstract][Full Text] [Related]
2. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. Dorian P; Al-Khalidi HR; Hohnloser SH; Brum JM; Dunnmon PM; Pratt CM; Holroyde MJ; Kowey P; J Am Coll Cardiol; 2008 Sep; 52(13):1076-83. PubMed ID: 18848141 [TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Dorian P; Borggrefe M; Al-Khalidi HR; Hohnloser SH; Brum JM; Tatla DS; Brachmann J; Myerburg RJ; Cannom DS; van der Laan M; Holroyde MJ; Singer I; Pratt CM; Circulation; 2004 Dec; 110(24):3646-54. PubMed ID: 15533855 [TBL] [Abstract][Full Text] [Related]
4. Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial. Robinson VM; Bharucha DB; Mahaffey KW; Dorian P; Kowey PR; Am Heart J; 2017 Mar; 185():43-51. PubMed ID: 28267474 [TBL] [Abstract][Full Text] [Related]
5. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Kaźmierczak J; Peregud-Pogorzelska M; Rzeuski R Pacing Clin Electrophysiol; 2007 Aug; 30(8):1043-6. PubMed ID: 17669094 [TBL] [Abstract][Full Text] [Related]
7. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators. Bollmann A; Husser D; Cannom DS Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525 [TBL] [Abstract][Full Text] [Related]
8. Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators. Reiffel JA Curr Cardiol Rep; 2007 Sep; 9(5):381-6. PubMed ID: 17877933 [TBL] [Abstract][Full Text] [Related]
9. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. Pratt CM; Al-Khalidi HR; Brum JM; Holroyde MJ; Schwartz PJ; Marcello SR; Borggrefe M; Dorian P; Camm AJ; J Am Coll Cardiol; 2006 Aug; 48(3):471-7. PubMed ID: 16875971 [TBL] [Abstract][Full Text] [Related]
10. Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. Hohnloser SH; Al-Khalidi HR; Pratt CM; Brum JM; Tatla DS; Tchou P; Dorian P; Eur Heart J; 2006 Dec; 27(24):3027-32. PubMed ID: 17050586 [TBL] [Abstract][Full Text] [Related]
11. The shocking story of azimilide. Hanna IR; Langberg JJ Circulation; 2004 Dec; 110(24):3624-6. PubMed ID: 15596558 [No Abstract] [Full Text] [Related]
12. The azimilide post-infarct survival evaluation (ALIVE) trial. Camm AJ; Karam R; Pratt CM Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221 [TBL] [Abstract][Full Text] [Related]
13. Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. Connolly SJ; Schnell DJ; Page RL; Wilkinson WE; Marcello SR; Pritchett EL; Am Heart J; 2003 Sep; 146(3):489-93. PubMed ID: 12947368 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study. Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH; Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672 [TBL] [Abstract][Full Text] [Related]
15. Azimilide for atrial fibrillation: clinical trial results and implications. Pritchett EL; Marcello SR Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716 [TBL] [Abstract][Full Text] [Related]
16. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A; Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368 [TBL] [Abstract][Full Text] [Related]
17. Azimilide: another effort to prevent implantable cardioverter-defibrillator shocks and their sequelae why it is important and how it works. Cannom DS; Gidney B J Am Coll Cardiol; 2008 Sep; 52(13):1084-5. PubMed ID: 18848142 [No Abstract] [Full Text] [Related]